Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Trial Profile

An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Emphysema
  • Focus Therapeutic Use
  • Acronyms RAPID Extension trial
  • Sponsors CSL Behring
  • Most Recent Events

    • 13 Sep 2018 According to a CSL Behring media release, results of the subgroup analysis of the RAPID trial programme will be presented at the 28th International Congress of the European Respiratory Society (ERS).
    • 24 May 2017 Results Post-Hoc Analysis of the RAPID/RAPID Extension Trialpresented at the 113th International Conference of the American Thoracic Society
    • 02 Dec 2016 Data from this trial published in the Lancet Respiratory Medicine, as per a CSL Behring media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top